DCIS: Biosignature Helps Guide Post-Lumpectomy Decisions DCIS: Biosignature Helps Guide Post-Lumpectomy Decisions
A new biosignature tool helps with treatment decisions after lumpectomy for ductal carcinoma in situ (DCIS), eg, by identifying those who can skip radiotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Hematology | Lumpectomy